Quantcast

Latest Humanized antibody Stories

2009-01-26 05:00:00

MOUNTAIN VIEW, Calif., Jan. 26 /PRNewswire/ -- Based on its recent analysis of the ophthalmic pharmaceuticals market, Frost & Sullivan recognizes ESBATech with the 2009 North American Frost & Sullivan Technology Innovation of the Year Award for its work in developing antibody fragments. The smaller size of ESBATech's proprietary single-chain antibody fragment therapeutics addresses and overcomes many of the challenges associated with whole antibodies when treating diseases of the...

2009-01-20 07:30:00

SAN FRANCISCO, Jan. 20 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that results presented at the 2009 Gastrointestinal Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, selectively delivers SN-38 to human colon carcinoma in animal models as an effective new therapy. SN-38 is the active metabolite of irinotecan, a...

2009-01-07 10:11:00

MORRIS PLAINS, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Cynthia L. Sullivan, President and Chief Executive Officer, will be presenting at the 27th Annual J.P. Morgan Healthcare Conference to be held in San Francisco, CA. Ms. Sullivan's presentation, which is scheduled for Thursday, January 15th at 1:30 p.m., will provide a...

2008-12-16 08:00:00

BURLINGAME, Calif., Dec. 16 /PRNewswire/ -- Epitomics, Inc., the world's sole provider of humanized rabbit monoclonal antibodies for therapeutic use, today announced the appointment of Zhiqiang An, Ph.D. as Chief Scientific Officer. Dr. An comes to Epitomics from Merck Research Laboratories, where he was Director of Biologics Research. He has over 12 years of experience in drug discovery and development in the biotech and pharmaceutical industries, focusing on therapeutic antibody discovery,...

2008-11-11 09:00:47

MORRIS PLAINS, N.J., Nov. 11, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Gerard G. Gorman, Senior Vice President, Finance and Business Development, and Chief Financial Officer, will be presenting at the Lazard Capital Markets 5th Annual Healthcare Conference to be held in New York City from November 18 - 19, 2008. Mr. Gorman's presentation,...

2008-10-30 09:00:41

MORRIS PLAINS, N.J., Oct. 30, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Cynthia L. Sullivan, President and Chief Executive Officer, will provide a corporate overview at the Oppenheimer 19th Annual Healthcare Conference in New York. The presentation, scheduled on November 4, 2008 at 4:00 p.m., can be downloaded simultaneously at...

2008-10-28 12:00:17

Seattle Genetics, Inc. (Nasdaq: SGEN) today presented preclinical data on SGN-70 at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco, California. SGN-70 is a humanized monoclonal antibody targeting CD70 that is in development as a novel therapy for autoimmune diseases. Seattle Genetics is currently conducting a phase I trial to assess the safety, tolerability and pharmacokinetics of SGN-70 in healthy volunteers. "CD70 is an ideal target for...

2008-10-25 21:00:20

BERKELEY, Calif., Oct. 25, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, today announced that its poster titled "Efficacy Of XOMA 052 Anti-IL-1 Beta Antibody In The DBA/1 Mouse Collagen-Induced Arthritis Model" will be presented at the American College of Rheumatology 2008 Annual Conference, on Sunday, October 26 from 9:00 AM until 11:00 AM in Hall A. The poster also contains data demonstrating that XOMA 052 blocks...

2008-10-15 12:00:34

Immunomedics, a biopharmaceutical company, has received a new US patent that covers the composition of matter and the use of humanized, chimeric and human anti-CD20 antibodies and antibody fusion proteins or fragments thereof comprising at least the veltuzumab antibody that targets the CD20 antigen present on B-lymphocytes, leukemias, and lymphomas. The allowed claims cover the use of veltuzumab and bispecific antibody protein constructs for the treatment and diagnosis of B-cell disorders,...

2008-10-14 09:00:11

MORRIS PLAINS, N.J., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that U.S. patent 7,435,803 was issued today covering the composition of matter and the use of humanized, chimeric and human anti-CD20 antibodies and antibody fusion proteins or fragments thereof comprising at least the veltuzumab antibody that targets the CD20 antigen present on...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related